Citigroup downgrades Sabra Health Care REIT to Neutral
Citigroup analyst Nick Joseph downgraded Sabra Health Care REIT from Buy to Neutral and lowered the price target to $19 from $24.

*this image is generated using AI for illustrative purposes only.
Citigroup analyst Nick Joseph has downgraded Sabra Health Care REIT from Buy to Neutral, citing a revised outlook. The firm also lowered its price target for the stock to $19 from the previous $24.
Rating and Price Target Changes
The downgrade reflects a shift in the investment stance on Sabra Health Care REIT. The adjustment in the price target suggests a recalibration of the stock's potential upside based on current market conditions.
| Metric | Previous | New |
|---|---|---|
| Rating | Buy | Neutral |
| Price Target | $24 | $19 |
What specific market conditions or operational factors prompted Citigroup to revise its outlook for Sabra Health Care REIT?
How might this downgrade influence other analysts' ratings and investor sentiment towards the healthcare REIT sector?
What are the potential risks or opportunities for Sabra Health Care REIT in the current economic environment that could affect its stock performance?


























